Skip to main content
Grant Details

Grant Number: 5R01CA097271-10 Interpret this number
Primary Investigator: Li, Christopher
Organization: Fred Hutchinson Cancer Research Center
Project Title: Risk Factors for Second Primary Breast Cancer Among Dcis Survivors
Fiscal Year: 2014
Back to top


Abstract

ABSTRACT: The proposed study is a competitive renewal of our currently funded project that is investigating how epidemiological factors, clinical and pathological characteristics, and tumor marker expression influence the risk of second primary invasive contralateral breast cancer among survivors of a first primary invasive breast cancer. Here we propose to expand this work by evaluating factors that are related to risk of second primary breast cancers among ductal carcinoma in situ (DCIS) survivors. Incidence rates of DCIS have increased 7.2- fold from 1980 to 2001 in the United States, largely as a result of widespread breast cancer screening. DCIS lesions are very responsive to available therapies, and five-year disease-specific survival rates are close to 100%. However, DCIS survivors have a 3.4 to 8.6-fold higher risk of developing a second breast cancer compared to the risk that women in the general population have of developing a first breast cancer. The recent rapid rise in DCIS incidence rates has translated into a large and growing population of DCIS survivors who are particularly susceptible to developing a second breast cancer. Not all DCIS patients will go on to develop a second breast cancer, so certain surgical and adjuvant therapy combinations for DCIS constitute over- treatment for those at low risk of a second breast cancer, while others constitute under-treatment for those at high risk. At present, however, there is a lack of meaningful prognosticators to indicate which DCIS survivors are at high or low risk of developing a second breast cancer. Such prognosticators could be important guides to help these patients and their clinicians choose the most appropriate course of therapy and subsequent follow-up care. We propose to investigate how epidemiological, clinical, and histopathological characteristics of DCIS impact the risk of second primary breast cancers among DCIS survivors. We will recruit 515 patients diagnosed with DCIS and a verified subsequent second primary in situ or invasive breast cancer, and a control group consisting of 1,030 patients diagnosed only with DCIS to address the following specific aims: 1) How do epidemiological risk factors for breast cancer, including reproductive characteristics, anthropometric measures, use of exogenous hormones, mammographic density, and family history of breast cancer, influence the risks of second primary breast cancer overall, contralateral second primary breast cancer, and ipsilateral second primary breast cancer among DCIS survivors?; and 2) How do the clinical and histopathological features of DCIS, including treatments, tumor grade, and histological subtype impact risks of second primary breast cancer overall, contralateral second primary breast cancer, and ipsilateral second primary breast cancer among DCIS survivors? The proposed study will provide important information to the rapidly growing population of DCIS survivors as its results may help modulate their risk of developing a second primary breast cancer and inform their decision-making regarding DCIS treatments and subsequent breast cancer screening.

Back to top


Publications

Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma.
Authors: Baglia M.L. , Tang M.C. , Malone K.E. , Porter P. , Li C.I. .
Source: Cancer causes & control : CCC, 2019 Jan; 30(1), p. 113-120.
EPub date: 2018-12-11.
PMID: 30539315
Related Citations

Family History and Risk of Second Primary Breast Cancer after In Situ Breast Carcinoma.
Authors: Baglia M.L. , Tang M.C. , Malone K.E. , Porter P. , Li C.I. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2018 03; 27(3), p. 315-320.
EPub date: 2018-01-16.
PMID: 29339357
Related Citations

Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer.
Authors: Chen L. , Malone K.E. , Li C.I. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015 Sep; 24(9), p. 1423-6.
EPub date: 2015-06-17.
PMID: 26084603
Related Citations

Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
Authors: Monsees G.M. , Malone K.E. , Tang M.T. , Newcomb P.A. , Li C.I. .
Source: Journal of the National Cancer Institute, 2011-12-07; 103(23), p. 1752-60.
EPub date: 2011-10-21.
PMID: 22021667
Related Citations

Relationship between diabetes and risk of second primary contralateral breast cancer.
Authors: Li C.I. , Daling J.R. , Tang M.T. , Malone K.E. .
Source: Breast cancer research and treatment, 2011 Jan; 125(2), p. 545-51.
EPub date: 2010-07-13.
PMID: 20625814
Related Citations

Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users.
Authors: Pitteri S.J. , Amon L.M. , Busald Buson T. , Zhang Y. , Johnson M.M. , Chin A. , Kennedy J. , Wong C.H. , Zhang Q. , Wang H. , et al. .
Source: Cancer research, 2010-11-01; 70(21), p. 8598-606.
EPub date: 2010-10-19.
PMID: 20959476
Related Citations

Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer.
Authors: Li C.I. , Daling J.R. , Porter P.L. , Tang M.T. , Malone K.E. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-11-10; 27(32), p. 5312-8.
EPub date: 2009-09-08.
PMID: 19738113
Related Citations

Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
Authors: Li C.I. , Daling J.R. , Porter P.L. , Tang M.T. , Malone K.E. .
Source: Cancer research, 2009-09-01; 69(17), p. 6865-70.
EPub date: 2009-08-25.
PMID: 19706753
Related Citations




Back to Top